TY - JOUR
T1 - Roles of Clinical Research Networks in Pediatric Drug Development
AU - Turner, Mark A.
AU - Attar, Sabah
AU - de Wildt, Saskia N.
AU - Vassal, Gilles
AU - Mangiarini, Laura
AU - Giaquinto, Carlo
N1 - Publisher Copyright:
© 2017 Elsevier HS Journals, Inc.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the “big picture.” An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development.
AB - The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the “big picture.” An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development.
KW - academia
KW - industry
KW - integrated drug development
KW - pediatrics
KW - research networks
UR - http://www.scopus.com/inward/record.url?scp=85029659672&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2017.09.001
DO - 10.1016/j.clinthera.2017.09.001
M3 - Review article
C2 - 28943118
AN - SCOPUS:85029659672
SN - 0149-2918
VL - 39
SP - 1939
EP - 1948
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 10
ER -